Scroll Back to Top

Study number 779857

Healthy Adults, age 18-65

Dates

Apr 23 2026-Jul 03 2026

Location

Dallas, Texas

Age

18-65

Gender

Male and Female

Smoker

Yes

Compensation

$12,049

Group

C3

Study Details

This is a research study for a drug approved by the U.S Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. This study drug is also being developed for the potential treatment of autoimmune diseases, conditions in which the immune system mistakenly attacks the body. 

Dallas, TX is currently recruiting Healthy Adults, ages 18-65. 

Refer a friend & receive $350 per qualified referral

Women Eligibility Criteria

  • Women can be of childbearing potential or non-childbearing potential.

Smoking Criteria

  • Smoking is allowed. 

Body Mass Index

  • Participants must have a BMI of:
    • 18-34

Screening procedures

  • Screening procedures for this study may include:
    • Vitals
    • Physical examination
    • Electrocardiogram (ECG)
    • Collection of blood samples
    • Drug and Alcohol testing  

Additional Details

Check-in: April 23

Check-out: April 24

Follow-up visits: April 26, 28, May 1, 4, 8, 15, 22, 29, Jun 5, 12, 19, 26, Jul 3

Phone calls: May 29, Jun 12, 26

BMI Calculator

Weight

Height

Feet Inches